Your browser does not support JavaScript!
COVID-19 : Découvrez les Plans de Continuité d’Activité des entreprises de la biotechnologies

Fabricants distributeurs d'instruments de mesure

389 entreprises et organismes intervenants dans le domaine 'Instruments de mesure', classés par activité.

Rejoignez la communauté
Trouvez du matériel
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 17/07/2020
Merck taps Novocure's cancer-fighting electric fields for new Keytruda combination study
Merck taps Novocure's cancer-fighting electric fields for new Keytruda combination study chale Thu, 07/16/2020 - 10:36 ...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 27/05/2020
Merck inks Themis buyout to join COVID-19 vaccine race
Merck inks Themis buyout to join COVID-19 vaccine race ntaylor Tue, 05/26/2020 - 05:54 ...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 13/05/2020
Skyhawk Therapeutics boosts Merck collab pact with added targets, upfront and biobucks
Merck has decided to double down on its research pact with startup Skyhawk Therapeutics as it expands the deal to now also cover autoimmune and metabolic diseases....
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 29/04/2020
Merck, slower than its peers, edges into COVID-19 fight
Almost all of Merck’s Big Pharma peers have either on their own or, increasingly, with a partner, geared up to fight the good fight against COVID-19....
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 28/04/2020
Merck joins Seattle consortium to uncover the coronavirus’ molecular workings
Merck & Co. has begun working with the non-profit Institute for Systems Biology and a consortium of companies to investigate the molecular mechanisms behind the novel coronavirus, in a bid to...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 16/04/2020
Lawrence lands Cardurion CEO job after helping ArQule to Merck buyout
Peter Lawrence has taken up the CEO job at Cardurion Pharmaceuticals, a Takeda-partnered biotech that is moving a heart failure drug through the clinic. Lawrence landed the gig on the strength of a...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 30/03/2020
ACC: Bayer and Merck's vericiguat leads off virtual meeting with positive phase 3 heart failure data
After teasing positive top-line results last November, a deeper dive into Merck & Co. and Bayer’s heart failure drug vericiguat helped kick off this year’s scientific meeting of the American...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 18/03/2020
Merck hits goal in cough phase 3 but yet to quash tolerability concern
Merck has linked gefapixant to statistically significant improvements in chronic cough patients in two phase 3 trials. The results cement Merck’s status as the front-runner in the race to develop a...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 19/02/2020
'Closer to the science': Why Amgen vets Harper and Seidenberg set up their own VC shop
After 17 years at Amgen, head of R&D Sean Harper was ready to get closer to the science. He reunited with his former colleague from Merck and Amgen, Beth Seidenberg, in Los Angeles and set up...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 24/01/2020
EuroBiotech Report—Roche SMA data, iOnctura, PDC*line, Targovax and Bayer
In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line....
www.fiercebiotech.com
Charger plus d'actualités